Skip to content

US · DERM · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Journey Medical Corporation (DERM) intrinsic value and stock valuation

$3.30as of 2026-11-21 · Mkt cap 176.14M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Journey Medical Corporation DCF and intrinsic value

InvestorsCraft values DERM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from DERM’s statements →

Journey Medical Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Scottsdale, AZ 85258 journeymedicalcorp.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$61.9M+6.8% 5y CAGRd
20142025
Net income
-$-11.43M
20142025
Free cash flow
-$-12.44M
20142025
Total equity
$31.9M+25.4% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$61.9M$56.1M$79.2M$73.7M$63.1M
Operating income-$-8.17M-$-13.68M-$-2.07M-$-27.52M-$-34.88M
Net income-$-11.43M-$-14.67M-$-3.85M-$-29.63M-$-43.99M
EPSd-$-466.53K-$-718.06K-$-211.19K-$-1.69M-$-2.54M
Operating cash flow-$-12.44M-$-9.13M$5.24M-$-13.53M-$-2.18M
Capital expenditure$0.00-$-15M-$-5M-$-20M-$-10M
Free cash flow-$-12.44M-$-9.13M$240K-$-33.53M-$-12.18M
Total assets$94.6M$80.2M$76.9M$105.2M$97.3M
Total debt$25.4M$25.7M$17.7M$23M$910K
Net debt$1.31M$5.4M-$-9.71M-$-9.04M-$-48.17M
Total equity$31.9M$20.1M$20.4M$17M$42M
Cash and short-term investments$24.1M$20.3M$27.4M$32M$49.1M
Income statement
20252024202320222021
Revenue$61.9M$56.1M$79.2M$73.7M$63.1M
Cost of revenue$25.2M$20.9M$26.7M$30.8M$32.1M
Gross profit$36.7M$35.3M$52.5M$42.9M$31.1M
Research and development expenses$480K$9.86M$7.54M$10.9M$16.6M
Selling, general and administrative expenses$44.4M$40.2M$43.9M$59.5M$39.8M
Other expenses$0.00-$-1.13M$3.14M$0.00$9.54M
Operating expenses$44.9M$48.9M$54.6M$70.4M$65.9M
Cost and expenses$70M$69.8M$81.3M$101.2M$98M
Interest income$590K$760K$320K$60K$0.00
Interest expense$3.7M$2.7M$1.7M$2.02M$7.03M
Depreciation and amortization$4.35M$3.52M$3.85M$4.37M$2.56M
Ebitda-$-3.33M-$-8.4M$1.92M-$-23.18M-$-32.77M
Operating income-$-8.17M-$-13.68M-$-2.07M-$-27.52M-$-34.88M
Total other income/expenses, net-$-3.2M-$-930K-$-1.56M-$-2.05M-$-7.48M
Income before tax-$-11.37M-$-14.61M-$-3.63M-$-29.57M-$-42.36M
Income tax expense$60K$60K$220K$60K$1.63M
Net income-$-11.43M-$-14.67M-$-3.85M-$-29.63M-$-43.99M
Weighted average shares outstanding$24.5M$20.4M$18.2M$17.5M$17.3M
Weighted average diluted shares outstanding$24.5M$20.4M$18.2M$17.5M$17.3M
Balance sheet
20252024202320222021
Cash and short-term investments$24.1M$20.3M$27.4M$32M$49.1M
Net receivables$29.8M$10.2M$15.2M$28.2M$23.1M
Inventory$9.62M$14.4M$10.2M$14.2M$9.86M
Total current assets$66.9M$48.2M$56.5M$77.7M$84.5M
Property, plant and equipment, net$110K$200K$100K$190K$90K
Goodwill and intangible assets$27.6M$31.9M$20.3M$27.2M$12.6M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$27.7M$32.1M$20.4M$27.5M$12.8M
Total assets$94.6M$80.2M$76.9M$105.2M$97.3M
Accounts payable$9.31M$16.1M$16.1M$37M$22.8M
Short-term debt$100K$710K$3.1M$3.03M$910K
Deferred revenue$0.00$0.00$50K$0.00$0.00
Total current liabilities$37.4M$35.2M$41.9M$66.8M$51.6M
Long-term debt$25.3M$25M$14.6M$19.9M$3.63M
Deferred revenue, non-current$0.00$0.00$0.00$0.00-$-10K
Total non-current liabilities$25.3M$25M$14.6M$21.4M$3.63M
Capital lease obligations$120K$200K$110K$190K$100K
Total liabilities$62.7M$60.2M$56.5M$88.2M$55.2M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-98.46M-$-87.03M-$-72.36M-$-68.5M-$-38.87M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$31.9M$20.1M$20.4M$17M$42M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$25.4M$25.7M$17.7M$23M$910K
Net debt$1.31M$5.4M-$-9.71M-$-9.04M-$-48.17M
Cash flow statement
20252024202320222021
Net income-$-11.43M-$-14.67M-$-3.85M-$-29.63M-$-43.99M
Depreciation and amortization$4.72M$3.42M$3.85M$4.37M$2.56M
Stock-based compensation$6.29M$6.1M$2.61M$4.42M$2.47M
Change in working capital-$-11.9M-$-3.77M-$-1.66M$6.19M$14.7M
Accounts receivable-$-19.34M$4.47M$12.6M-$-5.38M$770K
Inventory$4.81M-$-4.22M$3.95M$1.74M-$-8.46M
Accounts payable-$-7.27M-$-2.1M-$-18.42M$14.3M$21.7M
Net cash provided by operating activities-$-12.44M-$-9.13M$5.24M-$-13.53M-$-2.18M
Investments in property, plant and equipment$0.00-$-15M-$-5M-$-20M-$-10M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-15M-$-5M-$-20M-$-10M
Common stock issued$16.9M$8.29M$4.49M$140K$32.5M
Common stock repurchased$0.00$0.00$0.00-$-370K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$16.2M$17M-$-4.8M$16.5M$53M
Net change in cash$3.79M-$-7.13M-$-4.56M-$-17.08M$40.8M
Cash at end of period$24.1M$20.3M$27.4M$32M$49.1M
Operating cash flow-$-12.44M-$-9.13M$5.24M-$-13.53M-$-2.18M
Capital expenditure$0.00-$-15M-$-5M-$-20M-$-10M
Free cash flow-$-12.44M-$-9.13M$240K-$-33.53M-$-12.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Journey Medical Corporation

        Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

        CEO
        Claude Maraoui
        Employees
        58
        Beta
        1.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Journey Medical Corporation (DERM)?

        Journey Medical Corporation (DERM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is DERM undervalued?

        DERM trades at a price of $3.30 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.